Tiffany K Ricks

7PUBLICATIONS
85CO-AUTHORS
Molecular targetsMedical biotechnology not elsewhere classifiedPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Flight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|Oct 08, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.

Sundeep Agrawal, Clara Lee, William F Pierce

|Aug 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.

Jennifer J Gao, Christy L Osgood, Zhou Feng

|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari, Mirat Shah, Gwynn Ison

Pageof 2